State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai 200031, China.
Shanghai Institute of Immunology, State Key Laboratory of Oncogenes and Related Genes, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
J Mol Cell Biol. 2020 Nov 25;12(12):980-986. doi: 10.1093/jmcb/mjaa070.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）自 2019 年 12 月以来引发了全球严重的 2019 年冠状病毒病（COVID-19）大流行。人们迫切需要有效的预防和治疗 COVID-19 的方法。开发能够阻断病毒感染的治疗性中和抗体（NAb）是一种很有前途的方法，因为 NAb 已成功应用于治疗其他病毒感染。最近抗体技术的进步极大地加速了 SARS-CoV-2 NAb 的发现，其中许多目前正在临床试验中积极测试。在这里，我们回顾了用于 SARS-CoV-2 NAb 开发的方法，并讨论了突显抗体发现的新兴技术。我们进一步总结了这些抗体的共同特征，包括共享的中和表位和序列特征。
